▶ KLOW BLEND · SUBTOPIC · DOSING LITERATURE

KLOW BLEND Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of KLOW BLEND. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for KLOW BLEND reports the following route(s) of administration: Subcutaneous (research). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of KLOW BLEND.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for KLOW BLEND of approximately Per-component varies. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of KLOW BLEND. Refer to the original publication for full protocol detail.

Kotani M, Detheux M, Vandenbogaerde A, et al. (2001) reports the KLOW BLEND protocol used in The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of GPR54, published in J Biol Chem. See the source for the protocol-level dose range, frequency, and duration. link
Gimpl G, Fahrenholz F (2001) reports the KLOW BLEND protocol used in The oxytocin receptor system: structure, function, and regulation, published in Physiol Rev. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ Why is the KLOW shelf-life shorter than the components?

The reconstituted shelf-life is limited by the GHK-Cu component · copper-peptide complexes degrade faster than non-copper peptides in solution. Use within 14 days, protected from light.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · 2–8 °C protected from light, 12+ months

Reconstituted · 2–8 °C, 14 days protected from light (limited by GHK-Cu component)

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved as a finished drug under this combinatorial label. Per-component status varies.

WADA · Per-component WADA status varies. GHK-Cu, kisspeptin-10, and oxytocin are not currently listed. BPC-157 (if substituted in the formulation) is prohibited under S0.

◀ KLOW BLEND OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-19